Compare OZ & TNXP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OZ | TNXP |
|---|---|---|
| Founded | 2020 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 230.0M | 231.3M |
| IPO Year | N/A | N/A |
| Metric | OZ | TNXP |
|---|---|---|
| Price | $63.74 | $19.20 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $70.00 |
| AVG Volume (30 Days) | 12.9K | ★ 766.6K |
| Earning Date | 11-14-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $7,217,000.00 | ★ $10,299,000.00 |
| Revenue This Year | N/A | $14.79 |
| Revenue Next Year | N/A | $933.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 244.98 | N/A |
| 52 Week Low | $56.77 | $6.76 |
| 52 Week High | $82.89 | $130.00 |
| Indicator | OZ | TNXP |
|---|---|---|
| Relative Strength Index (RSI) | 62.40 | 56.16 |
| Support Level | $58.04 | $18.59 |
| Resistance Level | $61.75 | $20.24 |
| Average True Range (ATR) | 0.65 | 1.29 |
| MACD | 0.73 | 0.60 |
| Stochastic Oscillator | 98.40 | 81.63 |
Belpointe PREP LLC is a qualified opportunity fund. The company's investments consist of properties located in qualified opportunity zones for the development or redevelopment of multifamily, student housing, senior living, healthcare, industrial, self-storage, hospitality, office, mixed-use, data centers, and solar projects located throughout the United States and its territories. Company currently has two reporting segments, commercial: includes properties such as office, retail centers, and warehouses; and mixed-use: includes properties that blend both residential and retail components within a single real estate asset.
Tonix Pharmaceuticals Holding Corp is a biopharmaceutical company focused on developing, licensing and commercializing therapeutics to treat and prevent human disease and alleviate suffering. Tonix's development portfolio is focused on central nervous system (CNS) disorders. The company's immunology development portfolio consists of biologics to address organ transplant rejection, autoimmunity and cancer, including TNX-1500, which is a humanized monoclonal antibody targeting CD40-ligand (CD40L or CD154) being developed for the prevention of allograft rejection and for the treatment of autoimmune diseases. Tonix also has product candidates in development in the areas of rare disease and infectious disease.